Ukr.Biochem.J. 2025; Volume 97, Issue 3, May-Jun, pp. 65-72

doi: https://doi.org/10.15407/ubj97.03.065

Indices of liver and kidney function and the level of cytokines and tumor biomarkers in the serum of patients with hepatitis C and hepatocellular carcinoma

24.06.2025   Uncategorized   No comments

Othman A. Othman, Mahmoud Fadl Bakr*

Biochemistry Division, Chemistry Department, Faculty of Science,
Minia University, 61519, El-Minia, Egypt;
*e-mail: mahmoud.fadl@mu.edu.eg

Received: 02 March 2025; Revised: 27 May 2025;
Accepted: 11 June 2025; Available on-line: 07 July 2025

Hepatitis C virus (HCV) selectively targets the liver and causes persistent infection, often evading the immune system, leading to chronic liver failure, kidney disease and HCV-related hepatocellular carcinoma (HCC). This study aims to estimate the indices of liver and kidney functions and the level of inflammatory cytokines and tumor markers in patients with both HCV-positive chronic hepatitis and HCV-related HCC in comparison to HCV only patients and healthy controls. The study included 156 persons divided into four groups: control group I – 27 healthy individuals; HCV group – 45 patients with HCV (proved by PCR); HCC group – 42 patients with HCC (proved by radiological investigations and laboratory tests); HCV+HCC group – 42 patients with HCV and HCC (HCV – positive chronic hepatitis with HCC). Routine clinical tests for kidney and liver function were used. The levels of IL-6, IL-1B, TNF-α and tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and alpha-Fetoprotein (AFP) were examined by ELISA. The results showed a highly significant increase in ALT, ALP, and AST activity, as well as uric acid, urea and creatinine levels, with a significant decrease in albumin levels in HCC and HCV+HCC groups compared to HCV-only patients and healthy controls. The elevation in the serum levels of the studied tumor markers and cytokines in the HCC and HCV+HCC groups, with the highest levels in the latter, was observed. The data obtained indicate the progressive deterioration in liver and kidney functions and a significant effect of chronic inflammation in HCV-related liver carcinogenesis.

Keywords: , , , , , , ,

References:

  1. Pinion S. Virtual ESMO World Congress on Gastrointestinal Cancer 2021. Lancet Gastroenterol Hepatol. 2021;6(9):696. CrossRef
  2. Lowey B, Hertz L, Chiu S, Valdez K, Li Q, Liang TJ. Hepatitis C Virus Infection Induces Hepatic Expression of NF-κB-Inducing Kinase and Lipogenesis by Downregulating miR-122. mBio. 2019;10(4):e01617-e01619. PubMed, PubMed, CrossRef
  3. Murray CL, Rice CM. Turning hepatitis C into a real virus. Annu Rev Microbiol. 2011;65:307-327. PubMed, CrossRef
  4. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132(4):296-305. PubMed, CrossRef
  5. Droc G, Istrate M, Mercan-Stanciu A, Dodot M, Isac T, Toma L, Zgura A, Trifan A, Serbanica AN, Iliescu L, Micu L. Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients. In Vivo. 2022;36(6):2918-2922. PubMed, PubMed, CrossRef
  6. 6. Li Q, Lowey B, Sodroski C, Krishnamurthy S, Alao H, Cha H, Chiu S, El-Diwany R, Ghany MG, Liang TJ. Cellular microRNA networks regulate host dependency of hepatitis C virus infection. Nat Commun. 2017;8(1):1789. PubMed, PubMed, CrossRef
  7. 7. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450-1462. PubMed, CrossRef
  8. 8. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58(1):89-97. PubMed, CrossRef
  9. 9. Yoon JH, Park JY, Lee SM, Lee ES, Kim JH, Lee JM. Renal protection CT protocol using low-dose and low-concentration iodine contrast medium in at-risk patients of HCC and with chronic kidney disease: a randomized controlled non-inferiority trial. Cancer Imaging. 2023;23(1):100. PubMed, PubMed, CrossRef
  10. 10. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24(1):1-17. PubMed, CrossRef
  11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917. PubMed, CrossRef
  12. World Health Organization Cancer. (2021): https://www.who.int/news-room/fact-sheets/detail/cancer. Published September 21, Accessed September, 2021.
  13. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol. 2001;28(5):441-449. PubMed, CrossRef
  14. Ammerlaan W, Trezzi JP, Lescuyer P, Mathay C, Hiller K, Betsou F. Method validation for preparing serum and plasma samples from human blood for downstream proteomic, metabolomic, and circulating nucleic acid-based applications. Biopreserv Biobank. 2014;12(4):269-280. PubMed, CrossRef
  15. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31(1):87-96. PubMed, CrossRef
  16. Young DS. Effects of drugs on clinical laboratory tests. Ann Clin Biochem. 1997;34 ( Pt 6):579-581. PubMed, CrossRef
  17. Kind PR, King EJ. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol. 1954;7(4):322-326. PubMed, PubMed, CrossRef
  18. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56-63. PubMed, CrossRef
  19. Bowers LD, Wong ET. Kinetic serum creatinine assays. II. A critical evaluation and review. Clin Chem. 1980;26(5):555-561. PubMed
  20.  Shephard M, Mazzachi RD. The collection, preservation, storage and stability of urine specimens for routine clinical biochemical analysis. Clin Biochem Rev. 1983;4:61-67.
  21.  Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst. 1972;97(151):142-145. PubMed, CrossRef
  22. Helle M, Boeije L, de Groot E, de Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods. 1991;138(1):47-56. PubMed, CrossRef
  23. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin 1. Immunol Today. 1986;7(2):45-56. PubMed, CrossRef
  24. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266(12):7313-7316. PubMed
  25. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991;63(4):636-640. PubMed, PubMed, CrossRef
  26. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6(3):462-468. PubMed, CrossRef
  27. Wu JC, Lee SD, Hsiao KJ, Wang SS, Chou P, Tsao D, Tsai YT, Lui WY, Chiang JH, Lo KJ. Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan–a dried blood spot method. Liver. 1988;8(2):100-104. PubMed, CrossRef
  28. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-2576. PubMed, CrossRef
  29. Vescovo T, Refolo G, Romagnoli A, Ciccosanti F, Corazzari M, Alonzi T, Fimia GM. Autophagy in HCV infection: keeping fat and inflammation at bay. Biomed Res Int. 2014;2014:265353. PubMed, PubMed, CrossRef
  30. Muriel P. Role of free radicals in liver diseases. Hepatol Int. 2009;3(4):526-536. PubMed, PubMed, CrossRef
  31. Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean J Intern Med. 2018;33(4):670-678. PubMed, PubMed, CrossRef
  32. Huo TI, Lui WY, Wu JC, Huang YH, King KL, Loong CC, Lee PC, Chang FY, Lee SD. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg. 2004;28(3):258-262. PubMed, CrossRef
  33. Malaguarnera M, Di Fazio I, Laurino A, Romeo MA, Giugno I, Trovato BA. Role of interleukin 6 in hepatocellular carcinoma. Bull Cancer. 1996;83(5):379-384. PubMed
  34. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M, Rose-John S, Della Rocca C, Tripodi M, Lazzaro D, Taub R, Savino R, Ciliberto G. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998;17(19):5588-5597. PubMed, PubMed, CrossRef
  35. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204. PubMed, PubMed, CrossRef
  36. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;11(42):6624-6630. PubMed, PubMed, CrossRef
  37. Moura AS, Carmo RA, Teixeira AL, Rocha MO. Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C. Braz J Infect Dis. 2009;13(5):375-382. PubMed, CrossRef
  38. Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439-2446. PubMed, CrossRef
  39. Zhang W, Wang Y, Dong X, Yang B, Zhou H, Chen L, Zhang Z, Zhang Q, Cao G, Han Z, Li H, Cui Y, Wu Q, Zhang T, Song T, Li Q. Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma. Biosci Trends. 2022;15(6):397-405. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.